Lupin Brand Guidelines: Desh Bandhu Gupta’s 1968 Generics Maker, Named After a Flower

From a teaching post at Pilani to a Mumbai company.

Lupin is an Indian pharmaceutical company based in Mumbai whose business is mainly generic medicines. It was founded in 1968 by Desh Bandhu Gupta, who had been teaching chemistry at the Birla Institute of Technology and Science in Pilani, Rajasthan, according to English Wikipedia and the company’s own history. Wikipedia adds that funding from the Central Bank of India allowed the young company to open its first manufacturing facility.

The name is a plant’s. Lupin says the company “was named after a flower”: the lupin, which, in the company’s words, “grows even in harsh conditions and enriches the soil around it.” It tells its own start modestly, too, saying it began with just two employees, a packer and a part-time typist.

The first products were public-health staples. Lupin says it started as a maker of vitamins, and that its first major order came from the Government of India, which asked it to supply iron and folic acid tablets for a national mother-and-child health programme; English Wikipedia gives the same account. It then turned to tuberculosis drugs. The company dates its production of ethambutol, an anti-tuberculosis medicine, to 1981, and Wikipedia says anti-TB drugs once made up more than a third of its sales.

The company’s own timeline fills in the corporate steps. Lupin Laboratories was incorporated as a private company in 1972; the first formulations plant and research centre opened at Aurangabad in Maharashtra in 1979; plants at Mandideep, in Madhya Pradesh, and Ankleshwar, in Gujarat, came on stream in 1987; and the company says those two sites received their first US FDA approvals in 1989. Lupin Laboratories and a sister company, Lupin Chemicals, went public in 1993, and the two were merged into Lupin Limited in 2001, the year it opened Lupin Research Park in Pune. In 1988 Gupta set up the Lupin Human Welfare & Research Foundation, which works on rural development, and in 1999 Lupin became a founding member of the Indian Pharmaceutical Alliance, Wikipedia says.

From Aurangabad to Baltimore, Osaka and São Paulo.

Lupin went abroad in the 2000s. Its US company, Lupin Pharmaceuticals Inc., is based in Baltimore, Maryland; the company dates its founding to 2003 on one page and 2004 on another. It says it entered the US branded market in 2004 with Suprax, a cefixime antibiotic for children, and launched its US generics business in 2005 with four products. English Wikipedia names Suprax and the cholesterol drug Antara among its US brands.

Acquisitions followed on several continents. In Japan, Lupin bought Kyowa Pharmaceutical Industry in 2007 and I’rom Pharmaceutical in 2011, then sold Kyowa to the private-equity firm Unison in 2019, according to Wikipedia and the company. It bought Hormosan Pharma in Germany in 2008, a majority stake in Pharma Dynamics in South Africa the same year, and Multicare in the Philippines in 2009. In Latin America it bought Laboratorios Grin of Mexico, an eye-care company, in 2014 and Medquímica of Brazil in 2015. In the US it bought Gavis Pharma and Novel Laboratories; the company says Novel became Lupin Somerset, its first manufacturing site in the US, and that it opened a centre for inhalation research at Coral Springs, Florida, in 2015.

Wikipedia describes Lupin’s range as covering paediatrics, cardiovascular medicine, anti-infectives, diabetes, asthma and tuberculosis. More recent work, by the company’s own timeline, has moved into inhaled medicines and biosimilars: it lists a launch of its etanercept biosimilar in the European Union in 2020, the Luforbec inhaler in the UK in 2021 and the Rymti etanercept biosimilar in Canada in 2024, as well as purchases of brands from Boehringer Ingelheim, Menarini and Sanofi between 2023 and 2024. In May 2023 it agreed to buy the French company Medisol, Wikipedia says. In 2012, the company says, Lupin entered India’s NIFTY 50 share index.

Generic and specialty medicine makers.

Generic-medicine makers sell products that are, by design, meant to match medicines already on the market. That leaves their visual identity with an unusual job: it has to signal reliability and scale rather than novelty, and it often has to work on thousands of packs at once.

The pictures these companies publish tend to repeat a small set of scenes. There are close-ups of blister packs and plain white tablets, shot clean and bright against pale backgrounds. There are pharmacists at a counter handing a box across to a customer, a moment that puts a person between the product and the patient. And there are wide views of large production sites, with long corridors, stainless steel and staff in white coats and hairnets, used to suggest capacity and control.

Packaging is where the system shows most clearly. Because one company may carry a very large range of molecules and strengths, its packs usually rely on a fixed layout with colour bands, stripes or blocks that separate one product or dose from another, while the company name stays in the same place on every box. Corporate material then widens the frame: maps, globes and lines linking continents, meant to picture supply reaching many countries.

The same language appears on the trade-show floor. At industry fairs such as CPHI, where ingredient suppliers, contract manufacturers and generics companies meet, stands lean on large logos, simple colour fields and photographs of laboratories and plants. For a designer, the category is a study in restraint: a clear name, a disciplined colour system and imagery that keeps attention on trust and access.

Plants in India, a network abroad.

Most of the making happens in India. Lupin says it has 15 manufacturing facilities across the country and two research centres, in Pune and Aurangabad, and describes itself as having operations in 11 countries and more than 26,000 people. It names Manju Gupta as its chairperson.

Its newer sites sit both in India and abroad. The company’s timeline lists a dosage plant at Jammu from 2007, a plant at Pithampur from 2011, new plants at Visakhapatnam and at Tottori in Japan in 2016, a plant in Sikkim in 2017 and an injectables facility at Nagpur in 2018. It also bought Nanomi, a Dutch company working on complex injectables, in 2014, and the same year formed YL Biologics, a joint venture with the Toyama drug maker Yoshindo, Wikipedia says. In Australia it acquired the worldwide rights to Goanna, a pain-relief brand that Wikipedia describes as more than 100 years old.

Its factories have been through regulatory scrutiny. On 6 November 2017 the US FDA issued a warning letter covering Lupin’s plants at Goa and at Pithampur, near Indore. In July 2023 the company said the FDA had evaluated its corrective actions and found the issues in the letter satisfactorily resolved, IIFL reported on 28 July 2023.

For a design guide, Lupin shows how a plant name and a public-health origin can carry a corporate story across many markets. Compare Sun Pharma and Cipla, two other Indian generics makers. For this guide we use a violet and a leaf green with a serif, an unofficial interpretation; no product or logo is reproduced.

Keep Lupin’s identity on hand — save it to a board in the Made Good inspiration library.